AR035603A1 - Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos - Google Patents

Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos

Info

Publication number
AR035603A1
AR035603A1 ARP010105502A ARP010105502A AR035603A1 AR 035603 A1 AR035603 A1 AR 035603A1 AR P010105502 A ARP010105502 A AR P010105502A AR P010105502 A ARP010105502 A AR P010105502A AR 035603 A1 AR035603 A1 AR 035603A1
Authority
AR
Argentina
Prior art keywords
disorders
patient
manufacture
piperazine
derivatives
Prior art date
Application number
ARP010105502A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR035603A1 publication Critical patent/AR035603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de piperazina que comprenden un compuesto de acuerdo con la fórmula (3), en donde R1 es ciano, nitro, trifluorometilo o halógeno, o sus sales de adición de ácido farmacéuticamente aceptables, los cuales son útiles como antagonistas del receptor 5-HT1A. Además se describen composiciones farmacéuticas y el uso de dichos compuestos para la fabricación de un medicamento para el tratamiento de un paciente que sufre de trastornos del SNC, relacionado con la ansiedad o la depresión, la esquizofrenia, para el déficit de memoria o disfunción cognitiva, para el abuso de alcohol, nicotina, y de drogas, enfermedad de Parkinson y trastornos motores en un paciente, migrana, trastornos de la alimentación, disfunción sexual, incontinencia urinaria, ataque apopléjico, trastornos endocrinos, trastornos del sueno, trastornos del déficit de la atención en un paciente, tratamiento del síndrome de Tourette, el autismo, fobias sociales, trastornos de hiperactividad o trastornos termorreguladores en un paciente que lo necesita.
ARP010105502A 2000-11-28 2001-11-27 Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos AR035603A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25330100P 2000-11-28 2000-11-28
US29781401P 2001-06-13 2001-06-13

Publications (1)

Publication Number Publication Date
AR035603A1 true AR035603A1 (es) 2004-06-16

Family

ID=26943115

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105502A AR035603A1 (es) 2000-11-28 2001-11-27 Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos

Country Status (25)

Country Link
US (3) US6469007B2 (es)
EP (1) EP1339406B1 (es)
JP (1) JP4198989B2 (es)
KR (1) KR100835552B1 (es)
CN (1) CN100352437C (es)
AR (1) AR035603A1 (es)
AT (1) ATE269078T1 (es)
AU (2) AU2002237654B2 (es)
BR (1) BR0115609A (es)
CA (1) CA2428039C (es)
DE (1) DE60103927T2 (es)
DK (1) DK1339406T3 (es)
EA (1) EA005925B1 (es)
ES (1) ES2222401T3 (es)
HK (1) HK1057864A1 (es)
HU (1) HUP0400551A2 (es)
IL (1) IL156098A0 (es)
MX (1) MXPA03004677A (es)
NO (1) NO325501B1 (es)
NZ (1) NZ526150A (es)
PL (1) PL363219A1 (es)
PT (1) PT1339406E (es)
TR (1) TR200401546T4 (es)
TW (1) TWI224102B (es)
WO (1) WO2002044142A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
EP1408976B3 (en) 2001-07-20 2010-08-25 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
US7091349B2 (en) 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
AU2003220110B2 (en) 2002-03-12 2009-04-09 Wyeth Process for making chiral 1,4-disubstituted piperazines
RU2315762C2 (ru) 2002-03-12 2008-01-27 Уайт Способ синтеза хиральных n-арилпиперазинов
US7361773B2 (en) 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
KR100646337B1 (ko) * 2004-06-30 2006-11-23 주식회사 롯데기공 보일러의 누수 감지방법
ATE469174T1 (de) * 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
TW200700413A (en) * 2005-03-01 2007-01-01 Wyeth Corp Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
MX2007015772A (es) * 2005-06-17 2008-02-22 Wyeth Corp Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a.
WO2007089616A2 (en) * 2006-01-26 2007-08-09 The University Of Rochester Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives

Also Published As

Publication number Publication date
US20030022901A1 (en) 2003-01-30
IL156098A0 (en) 2003-12-23
KR20030051879A (ko) 2003-06-25
TWI224102B (en) 2004-11-21
WO2002044142A2 (en) 2002-06-06
EA200300619A1 (ru) 2003-10-30
DE60103927D1 (de) 2004-07-22
ES2222401T3 (es) 2005-02-01
EP1339406B1 (en) 2004-06-16
NO20032390D0 (no) 2003-05-27
JP2004520289A (ja) 2004-07-08
NO325501B1 (no) 2008-05-26
WO2002044142A3 (en) 2002-08-08
US6586436B2 (en) 2003-07-01
ATE269078T1 (de) 2004-07-15
PL363219A1 (en) 2004-11-15
NZ526150A (en) 2004-11-26
CN1477961A (zh) 2004-02-25
TR200401546T4 (tr) 2004-09-21
US20030216408A1 (en) 2003-11-20
EP1339406A2 (en) 2003-09-03
HUP0400551A2 (en) 2006-02-28
MXPA03004677A (es) 2003-09-05
DK1339406T3 (da) 2004-09-27
PT1339406E (pt) 2004-10-29
DE60103927T2 (de) 2005-06-23
US20020107254A1 (en) 2002-08-08
CA2428039C (en) 2011-08-09
US7026320B2 (en) 2006-04-11
CA2428039A1 (en) 2002-06-06
CN100352437C (zh) 2007-12-05
JP4198989B2 (ja) 2008-12-17
KR100835552B1 (ko) 2008-06-09
US6469007B2 (en) 2002-10-22
AU2002237654B2 (en) 2005-07-28
NO20032390L (no) 2003-07-22
AU3765402A (en) 2002-06-11
BR0115609A (pt) 2003-11-11
HK1057864A1 (en) 2004-04-23
EA005925B1 (ru) 2005-08-25

Similar Documents

Publication Publication Date Title
AR035603A1 (es) Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos
AR036208A1 (es) Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
AR031248A1 (es) Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
AR033525A1 (es) Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
SE0100567D0 (sv) Compounds
SE0402735D0 (sv) Novel compounds
UY28578A1 (es) Derivados de amida
JP2004504376A5 (es)
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
UY26291A1 (es) Compuestos químicos xxii
SE0104341D0 (sv) New use
HUP0302966A2 (hu) Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402422A2 (hu) Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ECSP066866A (es) Formas de dosificación y composiciones farmacéuticasreferencia a las solicitudes relacionadas
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia

Legal Events

Date Code Title Description
FC Refusal